CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins84% CONFIDENCEOverall confidence: 84%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or betterAmgen's[1] release is datelined Thousand Oaks, Oct. 6, 2023; PharmExec[3] and SoCalTech[4] both dated their reports 6 October 2023.
On 6 October 2023 Amgen completed its acquisition of Horizon Therapeutics for US$116.50 per share in cash, a transaction equity value of about US$27.8 billion that added Tepezza, Krystexxa and Uplizna.
$27.8B
1.00